EP Patent

EP3758676A1 — Pharmaceutical compositions comprising nebivolol

Assigned to Novaliq GmbH · Expires 2021-01-06 · 5y expired

What this patent protects

The present invention relates to pharmaceutical compositions comprising the selective beta 1(β1) - receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present …

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising the selective beta 1(β1) - receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

Drugs covered by this patent

Patent Metadata

Patent number
EP3758676A1
Jurisdiction
EP
Classification
—
Expires
2021-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.